Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB-201 in mild to moderate ulcerative colitis
NCT01839214Phase 2Completed
- Sponsor
- VBL Therapeutics
- Start
- Jan 2013
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in ulcerative colitis (UC) comparing VB-201 160mg with Placebo -> VB-201 (2 arms). Primary endpoint: Modified Mayo Score indicating remission at 24 weeks. Started Jan 2013; status: completed.
02
Drugs
VB-201
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01839214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01839214.